Against this background we designed the study PIKTAM to prospectively evaluate efficacy and safety of a pan‐PI3K inhibitor, buparlisib, in combination with tamoxifen in HR+ mBC patients stratified by biomarkers of pathway activation, determined both in tumor tissue and cfDNA. Here, PIK3CG is linked to neoplasm.